messaggio

clik on the image and visit the new site

New site clik on the image

New site clik on the image

"In silico"


 From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
 Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Wednesday 10 June 2009

Economics of Antibiotic Resistance



From Expert Review of Anti-Infective Therapy

Economics of Antibiotic Resistance

by Oguz Resat Sipahi

Published: 09/30/2008


"The importance of phage therapy and associated research may increase proportionately with the incidence of pandrug-resistant microorganisms. Although it may be considered a kind of individualized therapy and may need complex technical equipment, the cost of phage therapy was found to be less than vancomycin, linezolid, teicoplanin and quinopristin/dalfopristin in the treatment of staphylococcal infections.[138]"
Posted by Rodolfo Berretti at 23:16
Labels: ,